Acute & Chronic Kidney InjuryArchives
Pathophysiology, risk factors and clinical management for polymyxin-associated acute kidney injury
Polymyxins serve as a 'last-line' defence against Gram-negative bacterial infections and are frequently used in critically ill patients with multidrug-resistant pathogens. However, polymyxin-associated acute kidney injury (PA-AKI) remains a major factor limiting their clinical application. This review...
Recombinant alpha-1 microglobulin to improve outcomes in survivors of AKI
Acute kidney injury (AKI) is a serious and common complication among patients undergoing major surgery. The underlying pathophysiologic mechanism includes ischemia-reperfusion injury, complement activation, oxidative stress, and heme toxicity. Among potential preventive measures, recombinant alpha-1...
Glucose-6-Phosphate Dehydrogenase Deficiency Is Associated With Increased Risk of Acute Kidney Injury Independent of Hemolytic Complications in Children With Severe Malaria
Acute kidney injury (AKI) is common and predicts mortality in severe malaria. Studies have reported an increased incidence of AKI in males with hemolytic features of severe malaria. Glucose-6-phosphate dehydrogenase (G6PD) deficiency, an X-linked enzymopathy, can induce hemolysis. We evaluated whether...
Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study
To clarify the relationship between acute kidney injury (AKI) and vancomycin use in patients with renal impairment and to establish a risk score for AKI. Methods: In this retrospective, multicentre, observational cohort study, trough and peak blood samples were collected from patients who initiated vancomycin...
Reduction of Vancomycin-Associated Acute Kidney Injury With Montelukast
Vancomycin ranks among the most utilized antimicrobial agents in the treatment of serious β-lactam-resistant gram-positive infections, but its use has been associated with nephrotoxicity. Reduction of acute kidney injury (AKI) has been reported in preclinical models with adjuvant montelukast. The...
